12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GKT137831: Additional Phase I data

Pooled data from 84 healthy male volunteers in a pair Phase I trials showed that single and multiple doses of oral GKT137831 were well tolerated with no dose-limiting toxicities (DLTs) or serious adverse events reported. The open-label Phase I...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >